Search clinical trials for: camrelizumab apatinib TMZ

Total 4090 results

Peking University Cancer Hospital & Institute

Recruiting

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Acral Melanoma

China
Peking Union Medical College Hospital

Completed

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC)

Cholangiocarcinoma | Hepatobiliary Neoplasm | Biliary Tract Cancer | Biomarker

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

Esophageal Cancer by AJCC V8 Stage

China
Hebei Medical University Fourth Hospital

Recruiting

Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor

Advanced Solid Tumor

China
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Gestational Trophoblastic Neoplasia

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification (TRIPLET-III)

C-staged Hepatocellular Carcinoma in BCLC Classification

China
The Affiliated Hospital of Qingdao University

Unknown

The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy

Lung Cancer

China
Fujian Medical University

Recruiting

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Xiangya Hospital of Central South University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Gastrointestinal Stromal Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer

Hepatocellular Carcinoma

China
Zhejiang University

Recruiting

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma (CAPT)

Hepatocellular Carcinoma

China
Sun Yat-sen University

Active, not recruiting

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Nasopharyngeal Carcinoma | Chemotherapy Effect | Immunotherapy | Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma | Molecular Targeted Therapy

China
Qianfoshan Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer

Immune Checkpoint Inhibition

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer

China
Fudan University

Recruiting

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

Gastric Cancer | Metastasis

China
Henan Cancer Hospital

Recruiting

Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer (CAMERA)

Small Cell Lung Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Hepatocellular Carcinoma (HCC)

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Harbin Medical University

Recruiting

An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

Gastrointestinal Cancer | Immunotherapy | Targeted Therapy

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

Sarcoma
Ruijin Hospital

Active, not recruiting

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

Intrahepatic Cholangiocarcinoma

China
Sun Yat-sen University

Recruiting

Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma (C-couple)

Hepatocellular Carcinoma

China
Beijing Tsinghua Chang Gung Hospital

Unknown

Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer

Hepatocellular Carcinoma
Beijing Hospital
Chinese Society of Clinical Oncology

Recruiting

Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases

Solid Tumor

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

Stage III Hepatocellular Cancer (CNLC Staging)

China
Hunan Cancer Hospital
Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Recruiting

A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).

Hepatocellular Carcinoma | Immune Checkpoint Inhibitors

China
Peking University First Hospital

Not yet recruiting

Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma

Renal Cell Carcinoma
ShiYue Li

Unknown

Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer (CCA-MPLC)

Lung Cancer
Zhejiang University
Huashan Hospital; West China Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Unknown

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

Hepatocellular Carcinoma | Liver Transplant

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

Advanced Gastric Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma

Pancreatic Cancer

China
Xuanwu Hospital, Beijing

Recruiting

Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

Chordoma | Chemotherapy Effect

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Apatinib Mesylate

Solid Tumor

China
Sun Yat-sen University

Completed

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

Recurrent Cervical Carcinoma | Metastatic Cervical Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

Hepatocellular Carcinoma Resectable
Guangxi Medical University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Not yet recruiting

Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma
Beijing Chest Hospital

Not yet recruiting

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Non-small Cell Lung Cancer
HRYZ Biotech Co.

Recruiting

MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

Sarcoma

China
First Affiliated Hospital Xi'an Jiaotong University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer (CCWSA/OAFLAG)

Locally Advanced Gastric Cancer

China
Shanghai Zhongshan Hospital

Recruiting

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Immunotherapy | Molecular Targeted Therapy

China
Beijing Friendship Hospital

Completed

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Biliary Tract Cancer | Capecitabine | Targeted Molecular Therapy | Anti-PD-1 Therapy

China
Fudan University

Not yet recruiting

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

Thyroid Cancer

China
Sun Yat-sen University

Recruiting

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

Nasopharyngeal Carcinoma

China
Ruijin Hospital

Recruiting

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Peripheral T Cell Lymphoma

China
Sun Yat-sen University

Not yet recruiting

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China

3

Subscribe